Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Interest & Investment Income: 2012-2025

Historic Interest & Investment Income for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to $13.4 million.

  • Agios Pharmaceuticals' Interest & Investment Income rose 2.37% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.0 million, marking a year-over-year increase of 60.20%. This contributed to the annual value of $48.1 million for FY2024, which is 44.20% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Interest & Investment Income is $13.4 million, which was down 7.88% from $14.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Interest & Investment Income high stood at $18.0 million for Q4 2024, and its period low was -$92,000 during Q2 2021.
  • Moreover, its 3-year median value for Interest & Investment Income was $8.9 million (2024), whereas its average is $11.4 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first plummeted by 105.20% in 2021, then surged by 2,048.91% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $332,000 in 2021, then skyrocketed by 1,854.22% to $6.5 million in 2022, then soared by 32.92% to $8.6 million in 2023, then soared by 108.89% to $18.0 million in 2024, then grew by 2.37% to $13.4 million in 2025.
  • Its last three reported values are $13.4 million in Q3 2025, $14.5 million for Q2 2025, and $16.1 million during Q1 2025.